Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020

被引：2
|
作者：
Moneer, Osman [1 ,2 ]
Lee, ChangWon C. [1 ]
Avorn, Jerry [1 ]
Kesselheim, Aaron S. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon,Program Regu, Boston, MA 02115 USA
[2] Yale Univ, Yale Sch Med, New Haven, CT USA
来源：
JAMA NETWORK OPEN | 2021年 / 4卷 / 04期
关键词：
D O I：
10.1001/jamanetworkopen.2021.8530
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This cross-sectional study uses data from the US Food and Drug Administration (FDA) to review the postmarketing requirements and commitments attached to new vaccines approved for use in the past 15 years in the United States.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Postmarketing Safety of Vaccines Approved by the US Food and Drug Administration A Cohort Study
    Tau, Noam
    Yahav, Dafna
    Shepshelovich, Daniel
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (06) : 445 - +
  • [2] Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006-2020
    Lythgoe, M. P.
    Krell, J.
    Savage, P.
    Prasad, V.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1208 - 1211
  • [3] Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials
    Shepshelovich, Daniel
    Tibau, Ariadna
    Goldvaser, Hadar
    Molto, Consolacion
    Ocana, Alberto
    Seruga, Bostjan
    Amir, Eitan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18) : 1798 - +
  • [4] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
    Gizem Kayki-Mutlu
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394 : 839 - 852
  • [5] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
    Kayki-Mutlu, Gizem
    Michel, Martin C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2021, 394 (05) : 839 - 852
  • [6] Twenty Years of Targeted and Biologic Immunomodulatory Drugs: Postmarketing Modifications of Drug Labels Approved by the US Food and Drug Administration
    Berman, Julia
    Yavne, Yarden
    Edel, Yonatan
    Elkayam, Ori
    Furer, Victoria
    Shepshelovich, Daniel
    MAYO CLINIC PROCEEDINGS, 2022, 97 (08) : 1512 - 1522
  • [7] Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
    Alexander Egilman
    Joshua D. Wallach
    Jeremy Puthumana
    Audrey D. Zhang
    Jason L. Schwartz
    Joseph S. Ross
    Journal of General Internal Medicine, 2021, 36 : 3281 - 3284
  • [8] Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
    Egilman, Alexander
    Wallach, Joshua D.
    Puthumana, Jeremy
    Zhang, Audrey D.
    Schwartz, Jason L.
    Ross, Joseph S.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (10) : 3281 - 3284
  • [9] US Food and Drug Administration-Mandated Postmarketing Studies for High-risk Cardiovascular Devices Approved 2015-2019
    Hidano, Danelle
    Dhruva, Sanket S.
    Redberg, Rita F.
    JAMA INTERNAL MEDICINE, 2022, 182 (05) : 556 - 558
  • [10] Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
    Wallach, Joshua D.
    Luxkaranayagam, Anita T.
    Dhruva, Sanket S.
    Miller, Jennifer E.
    Ross, Joseph S.
    BMC MEDICINE, 2019, 17 (1)
12345